This report estimates the percentages and numbers of adults in the United States with indications for Pr EP consistent with the 2014 U. The prevalence of surveyed behaviors most closely related to those described as indications for Pr EP in the 2014 guideline (6) were used to define the size of the target populations (Table 1).
The number of men aged 18–59 years not known to be HIV-positive who reported sex with a man in the past 12 months was derived from National Health and Nutrition Examination Survey (NHANES) data from 2007–2008, 2009–2010, and 2011–2012 .* The number of these MSM reporting sex with two or more men in the past 12 months and any condomless sex or sexually transmitted infections in the past 12 months was used to calculate the percentage of HIV-negative sexually active adult MSM with behavioral indications for Pr EP use. Estimates of MSM with indications for Pr EP did not consider injection risk.
Abstract Background: In 2014, approximately 40,000 persons in the United States received a diagnosis of human immunodeficiency virus (HIV) infection.
Preexposure prophylaxis (Pr EP) with daily oral antiretroviral medication is a new, highly effective intervention that could reduce the number of new HIV infections.
Delivering Pr EP in conjunction with other effective prevention services and associated preventive health care (e.g., hepatitis B vaccination and hepatitis B or C treatment when indicated) can be expected to reduce incident HIV infections and other preventable adverse health consequences for persons at risk.